Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38α mitogen-activated protein kinase mice

Free Radical Biology and Medicine

Volumn 49, Issue 9, 2010, Pages 1422-1431

  Thandavarayan, Rajarajan A ^a   Watanabe, Kenichi ^a   Sari, Flori R ^a   Ma, Meilei ^a   Lakshmanan, Arun Prasath ^a   Giridharan, Vijayasree V ^a   Gurusamy, Narasimman ^b   Nishida, Hiroshi ^a   Konishi, Tetsuya ^a   Zhang, Shaosong ^c   Muslin, Anthony J ^d   Kodama, Makoto ^e   Aizawa, Yoshifusa ^e  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LightLab Imaging Inc   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Apoptosis; Doxorubicin; Free radicals; Oxidative stress; P38 MAPK

Indexed keywords

CASPASE 3; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA DAMAGE; ELECTRON SPIN RESONANCE; ENZYME ACTIVATION; ENZYME REPRESSION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; IMMUNOFLUORESCENCE; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; APOPTOSIS; CASPASE 3; DNA DAMAGE; DOXORUBICIN; HEART; MICE; MICE, TRANSGENIC; MUTANT PROTEINS; MYOCYTES, CARDIAC; NADPH OXIDASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RESPIRATORY FUNCTION TESTS; TUMOR SUPPRESSOR PROTEIN P53; VENTRICULAR DYSFUNCTION, LEFT;

MUS; MUS MUSCULUS;

EID: 77957132594     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.08.005     Document Type: Article

References (55)

1. Ganey P.E., Carter L.S., Mueller R.A., Thurman R.G. Doxorubicin toxicity in perfused rat heart: decreased cell death at low oxygen tension. Circ. Res. 1991, 68:1610-1613.
2. 2. Ann. Oncol. 2000, 11:1029-1033.
3. Kluza J., Marchetti P., Gallego M.A., Lancel S., Fournier C., Loyens A., et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004, 23:7018-7030.
4. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 2007, 49:330-352.
5. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J. Med. 1998, 339:900-905.
6. Li T., Singal P.K. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000, 102:2105-2110.
7. Ushio-Fukai M., Alexander R.W., Akers M., Griendling K.K. p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II: role in vascular smooth muscle cell hypertrophy. J. Biol. Chem. 1998, 273:15022-15029.
8. Force T., Bonventre J.V. Growth factors and mitogen-activated protein kinases. Hypertension 1998, 31:152-161.
9. Lemke L.E., Bloem L.J., Fouts R., Esterman M., Sandusky G., Vlahos C.J. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. J. Mol. Cell. Cardiol. 2001, 33:1527-1540.
10. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 2004, 68:320-344.
11. Wang Y., Huang S., Sah V.P., Ross J., Brown J.H., Han J., et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J. Biol. Chem. 1998, 273:2161-2168.
12. Venkatakrishnan C.D., Tewari A.K., Moldovan L., Cardounel A.J., Zweier J.L., Kuppusamy P., et al. Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2680-H2691.
13. Lou H., Danelisen I., Singal P.K. Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H1925-H1930.
14. Tamura K., Sudo T., Senftleben U., Dadak A.M., Johnson R., Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 2000, 102:221-231.
15. Zhang S., Weinheimer C., Courtois M., Kovacs A., Zhang C.E., Cheng A.M., et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J. Clin. Invest. 2003, 111:833-841.
16. Meyer D., Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995, 378:386-390.
17. Thandavarayan R.A., Watanabe K., Ma M., Veeraveedu P.T., Gurusamy N., Palaniyandi S.S., et al. 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem. Pharmacol. 2008, 75:1797-1806.
18. Thandavarayan R.A., Watanabe K., Ma M., Gurusamy N., Veeraveedu P.T., Konishi T., et al. Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H911-H919.
19. Kalyanaraman B., Sealy R.C., Sinha B.K. An electron spin resonance study of the reduction of peroxides by anthracycline semiquinones. Biochim. Biophys. Acta 1984, 799:270-275.
20. Shioji K., Kishimoto C., Nakamura H., Masutani H., Yuan Z., Oka S., et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002, 106:1403-1409.
21. Miller F.J., Gutterman D.D., Rios C.D., Heistad D.D., Davidson B.L. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ. Res. 1998, 82:1298-1305.
22. Takaya T., Kawashima S., Shinohara M., Yamashita T., Toh R., Sasaki N., et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 2006, 186:402-410.
23. Neilan T.G., Blake S.L., Ichinose F., Raher M.J., Buys E.S., Jassal D.S., et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007, 116:506-514.
24. Chaubey R.C., Bhilwade H.N., Rajagopalan R., Bannur S.V. Gamma ray induced DNA damage in human and mouse leucocytes measured by SCGE-Pro: a software developed for automated image analysis and data processing for comet assay. Mutat. Res. 2001, 490:187-197.
25. Wold L.E., Aberle N.S., Ren J. Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect. Prev. 2005, 29:294-299.
26. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
27. Kitiyakara C., Chabrashvili T., Chen Y., Blau J., Karber A., Aslam S., et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J. Am. Soc. Nephrol. 2003, 14:2775-2782.
28. Yen H.C., Oberley T.D., Vichitbandha S., Ho Y.S., St Clair D.K. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Invest. 1996, 98:1253-1260.
29. Olson L.E., Bedja D., Alvey S.J., Cardounel A.J., Gabrielson K.L., Reeves R.H. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 2003, 63:6602-6606.
30. Monti E., Prosperi E., Supino R., Bottiroli G. Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. Anticancer Res. 1995, 15:193-197.
31. Kang Y.J., Chen Y., Epstein P.N. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J. Biol. Chem. 1996, 271:12610-12616.
32. Kim J.K., Pedram A., Razandi M., Levin E.R. Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms. J. Biol. Chem. 2006, 281:6760-6767.
33. Weinstein D.M., Mihm M.J., Bauer J.A. Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J. Pharmacol. Exp. Ther. 2000, 294:396-401.
34. Nozaki N., Shishido T., Takeishi Y., Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004, 110:2869-2874.
35. Kunisada K., Negoro S., Tone E., Funamoto M., Osugi T., Yamada S., et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl Acad. Sci. USA 2000, 97:315-319.
36. Liu F.F., Stone J.R., Schuldt A.J., Okoshi K., Okoshi M.P., Nakayama M., et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H660-H666.
37. Tian W., Zhang Z., Cohen D.M. MAPK signaling and the kidney. Am. J. Physiol. Renal Physiol. 2000, 279:F593-F604.
38. Muller E., Burger-Kentischer A., Neuhofer W., Fraek M.L., Marz J., Thurau K., et al. Possible involvement of heat shock protein 25 in the angiotensin II-induced glomerular mesangial cell contraction via p38 MAP kinase. J. Cell. Physiol. 1999, 181:462-469.
39. Westermann D., Rutschow S., Van Linthout S., Linderer A., Bucker-Gartner C., Sobirey M., et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 2006, 49:2507-2513.
40. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury: relationship to ischemic preconditioning. Basic Res. Cardiol. 2002, 97:276-285.
41. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol. 2004, 4:372-377.
42. L'Ecuyer T., Sanjeev S., Thomas R., Novak R., Das L., Campbell W., et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1273-H1280.
43. Huang C., Ma W.Y., Maxiner A., Sun Y., Dong Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J. Biol. Chem. 1999, 274:12229-12235.
44. Kishi H., Nakagawa K., Matsumoto M., Suga M., Ando M., Taya Y., et al. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J. Biol. Chem. 2001, 276:39115-39122.
45. Shizukuda Y., Matoba S., Mian O.Y., Nguyen T., Hwang P.M. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol. Cell. Biochem. 2005, 273:25-32.
46. Toko H., Oka T., Zou Y., Sakamoto M., Mizukami M., Sano M., et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens. Res. 2002, 25:597-603.
47. Dowd N.P., Scully M., Adderley S.R., Cunningham A.J., Fitzgerald D.J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest. 2001, 108:585-590.
48. Kotamraju S., Konorev E.A., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: role of reactive oxygen and nitrogen species. J. Biol. Chem. 2000, 275:33585-33592.
49. Kalivendi S.V., Kotamraju S., Zhao H., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase: effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. 2001, 276:47266-47276.
50. Konorev E.A., Kotamraju S., Zhao H., Kalivendi S., Joseph J., Kalyanaraman B. Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. Free Radic. Biol. Med. 2002, 33:988.
51. Kang Y.J., Chen Y., Yu A., Voss-McCowan M., Epstein P.N. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J. Clin. Invest. 1997, 100:1501-1506.
52. Zhang G.X., Kimura S., Nishiyama A., Shokoji T., Rahman M., Abe Y. ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction. Hypertension 2004, 43:117-124.
53. Parinandi N.L., Kleinberg M.A., Usatyuk P.V., Cummings R.J., Pennathur A., Cardounel A.J., et al. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003, 284:L26-L38.
54. Lal A.S., Clifton A.D., Rouse J., Segal A.W., Cohen P. Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. Biochem. Biophys. Res. Commun. 1999, 259:465-470.
55. Yamamori T., Inanami O., Nagahata H., Cui Y., Kuwabara M. Roles of p38 MAPK, PKC and PI3-K in the signaling pathways of NADPH oxidase activation and phagocytosis in bovine polymorphonuclear leukocytes. FEBS Lett. 2000, 467:253-258.